| Address:
|
FIRST FLOOR, BLOCK 3, THE OVAL,
SHELBOURNE ROAD, BALLSBRIDGE |
| City: |
DUBLIN |
|
State: |
|
|
Zip Code: |
00000 |
| Telephone: |
353 1 6699 020 |
|
Description of Business
|
Primary SIC Code:
2834 |
| (As filed with the SEC)
|
|
|
Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin's cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin's pipeline also includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease and epilepsy, all of which are available for partnering. Amarin is listed in the U.S. on the NASDAQ Capital Market ("AMRN"). For more information please visit www.amarincorp.com. ... More ... |
| Date |
12-mos
Rolling EPS |
Dividend |
P/E
Ratio |
| 09/2011 | -2.55 | NA | N/E | | 06/2011 | -3.44 | NA | N/E | | 03/2011 | -2.28 | NA | N/E | | 12/2010 | -2.49 | NA | N/E | | 12/2009 | -1.40 | NA | N/E | | 12/2008 | -0.91 | NA | N/E | | 06/2008 | -1.67 | NA | N/E | | 03/2008 | -3.52 | NA | N/E |
Key Financial Ratios and Statistics |
FYE:
12/31 |
| Profitability |
2010 |
Leverage |
2010 |
| Net Inc/Comm Equity | -0.84 | Total Liab/Total Assets | 6.72 | | Net Inc/Total Assets | -7.06 | Total Liab/Inv Cap | 8.55 | | Net Inc/Inv Cap | -8.98 | Total Liab/Comm Equity | 0.80 | | Pretax Inc/Net Sales | NA | Interest Coverage Ratio | -13161.63 | | Net Inc/Net Sales | NA | Curr Debt/Equity | NA | | Cash Flow/Net Sales | NA | LTD/Equity | 0.00 | | SG&A/NetSales | NA | Total Debt/Equity | 0.00 |
| Asset Utilization
|
|
Liquidity |
|
| Net Receivables Turnover | NA | Quick Ratio | 4.37 | | Inventory Turnover | NA | Current Ratio | 4.37 | | Inventory Day Sales | NA | Net Rec/Curr Assets | 0.02 | | Net Sales/Work Cap | NA | Inv/Curr Assets | NA | | Net Sales/PP&E | NA | | |
Income Statement (Millions) |
| |
9/30/2011
|
6/30/2011
|
3/31/2011
|
|
Total Revenues(Net Sales)
|
0.00
|
0.00
|
0.00
|
|
Cost of Goods Sold
|
NA
|
NA
|
NA
|
|
Selling & Admin Exps
|
3.43
|
10.03
|
2.73
|
|
Operating Income
|
-9.45
|
-15.21
|
-7.18
|
|
Interest Exp
|
NA
|
NA
|
NA
|
|
Pretax Income
|
97.11
|
-200.47
|
18.25
|
|
Other Income
|
106.65
|
-185.35
|
25.42
|
|
Net Income Bef Extraordinary ...
|
NA
|
NA
|
NA
|
|
Net Income
|
96.35
|
-202.10
|
18.29
|
|
Assets
|
9/30/2011
|
6/30/2011
|
3/31/2011
|
|
Cash & Short Term Investments
|
125.86
|
131.45
|
129.48
|
|
Receivables - Total
|
NA
|
NA
|
NA
|
|
Inventories - Total
|
NA
|
NA
|
NA
|
|
Total Current Assets
|
128.07
|
132.58
|
130.57
|
|
Net Property, Plant & Equipment
|
0.07
|
0.07
|
0.07
|
|
Total Assets
|
131.67
|
135.52
|
132.81
|
|
Liabilities
|
|
|
|
|
Accounts Payable
|
6.43
|
3.77
|
3.92
|
|
Debt in Current Liabilities
|
NA
|
NA
|
NA
|
|
Total Current Liabilities
|
6.43
|
3.77
|
3.92
|
|
Long-Term Debt
|
0.56
|
285.98
|
0.52
|
|
Total Liabilities
|
162.01
|
290.24
|
179.26
|
|
Stockholder's Equity
|
|
|
|
|
Minority Interest
|
NA
|
NA
|
NA
|
|
Preferred Stock
|
NA
|
NA
|
NA
|
|
Common Stock
|
113.28
|
111.23
|
105.62
|
|
Retained Earnings
|
-586.80
|
-683.14
|
-481.04
|
|
Treasury Stock
|
-0.22
|
-0.22
|
-0.22
|
|
Total Stockholders' Equity
|
-30.34
|
-154.72
|
-46.45
|
|
Total Liabilities and Stockholders' Equity
|
131.67
|
135.52
|
132.81
|
Cash Flow Summary (Millions) |
|
Categories
|
9/30/2011
|
6/30/2011
|
3/31/2011
|
|
Net Cash Provided by Operating Activities
|
-8.28
|
-10.78
|
-8.81
|
|
Net Cash Provided by Investing Activities
|
-1.67
|
-0.01
|
0.00
|
|
Net Cash Provided by Financing Activities
|
4.36
|
12.75
|
106.85
|
Annual Summary Data (Millions) |
| Year |
Sales |
Net
Income |
EPS |
| 12/2006 | 0.11 | -23.71 | -- | | 12/2007 | 0.00 | -37.80 | -- | | 12/2008 | 0.00 | -20.02 | -0.91 | | 12/2009 | 0.00 | -30.61 | -1.40 | | 12/2010 | 0.00 | -249.59 | -2.49 | | Growth Rates | -100.00 | -- | -- |
| Type |
Date(Q,M) |
No.
Owners |
Shares
Held (000s) |
%
Own |
| Institutional | 12/31/11 | 141 | 95,043 | 70.14 |
|
Report Date :
1/30/2012
 Copyright
2012, EDGAR Online, Inc. All
rights reserved. Replication or redistribution of EDGAR Online, Inc. content is
expressly prohibited without the prior written consent of EDGAR Online, Inc.
EDGAR Online, Inc. shall not be liable for any errors or delays in the content,
or for any actions taken in reliance thereon.
|
|
|